CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions

Autor: Xavier Rossello, Antonio Rodriguez-Sinovas, Gemma Vilahur, Verónica Crisóstomo, Inmaculada Jorge, Carlos Zaragoza, José L. Zamorano, Javier Bermejo, Antonio Ordoñez, Lisardo Boscá, Jesús Vázquez, Lina Badimón, Francisco M. Sánchez-Margallo, Francisco Fernández-Avilés, David Garcia-Dorado, Borja Ibanez

Publikováno v: Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)

Abstract Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinica

Externí odkaz: https://doaj.org/article/b7451e7937ac4d0583664f00519c9d62

Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry

Autor: Vicente Bertomeu‐Gonzalez, José Moreno‐Arribas, María Asunción Esteve‐Pastor, Inmaculada Roldán‐Rabadán, Javier Muñiz, Paula Raña‐Míguez, Martín Ruiz‐Ortiz, Ángel Cequier, Vicente Bertomeu‐Martínez, Lina Badimón, Manuel Anguita, Gregory Y. H. Lip, Francisco Marín

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 1 (2020)

Background Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the association between obesity and adverse events in patients receiving oral anticoagulants for AF. Methods and Results Cons

Externí odkaz: https://doaj.org/article/c7ef0660a3494c2ea72f49262f437615

Quality markers in cardiology: measures of outcomes and clinical practice —a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery1

Autor: José-Luis López-Sendón, José Ramón González-Juanatey, Fausto Pinto, José Cuenca Castillo, Lina Badimón, Regina Dalmau, Esteban González Torrecilla, José Ramón López Mínguez, Alicia M. Maceira, Domingo Pascual-Figal, José Luis Pomar Moya-Prats, Alessandro Sionis, José Luis Zamorano

Publikováno v: Cirugía Cardiovascular, Vol 22, Iss 6, Pp 315-324 (2015)

Externí odkaz: https://doaj.org/article/de08ce7d4b2a4ff0ad3a8c5841a39880

A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation:effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry

Autor: María Asunción Esteve-Pastor, José Miguel Rivera-Caravaca, Martín Ruiz-Ortiz, Javier Muñiz, Inmaculada Roldán-Rabadán, Déborah Otero, Raquel López-Gálvez, Ángel Cequier, Vicente Bertomeu-Martínez, Lina Badimón, Manuel Anguita, Gregory Y.H. Lip, Francisco Marín

Publikováno v: Esteve-Pastor, M A, Rivera-Caravaca, J M, Ruiz-Ortiz, M, Muñiz, J, Roldán-Rabadán, I, Otero, D, López-Gálvez, R, Cequier, Á, Bertomeu-Martínez, V, Badimón, L, Anguita, M, Lip, G Y H, Marín, F & FANTASIIA Investigators 2022, ' A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation : effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry ', Expert Opinion on Pharmacotherapy, vol. 23, no. 12, pp. 1457-1465 . https://doi.org/10.1080/14656566.2022.2109961
EXPERT OPINION ON PHARMACOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

INTRODUCTION: For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting oral anticoagulants (DOAC) are at least as effective and safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99941a30dd09a692d597242ea3d06f68
https://vbn.aau.dk/da/publications/8d9f9409-7ffd-4bb8-a057-f3dd8b9ee797

Incidencia de eventos cardiovasculares y cambios en el riesgo estimado y en el tratamiento de la hipercolesterolemia familiar: registro SAFEHEART

Autor: Leopoldo Pérez de Isla, Raquel Arroyo-Olivares, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Daniel Zambón, Francisco Fuentes, Nelva Mata, Mar Piedecausa, M. Dolores Mañas, Juan F. Sánchez Muñoz-Torrero, José Pablo Miramontes-González, Raimundo de Andrés, Marta Mauri, Rocío Aguado, Ángel Brea, José M. Cepeda, José I. Vidal-Pardo, Ceferino Martínez-Faedo, Miguel Ángel Barba, Rosa Argüeso, Enrique Ruiz-Pérez, Alfredo Michán, Francisco Arrieta, María Riestra Fernández, Leire Pérez, José M. Pinilla, Gonzalo Díaz-Soto, Xavier Pintó, Teresa Padró, Lina Badimón, Pedro Mata, Begoña Perez-Corral, Fátima Almagro, Raquel Arroyo, Adriana Saltijeral, Daniel Mosquera, Marta Casañas, Julio Carbayo, Jose María Cepeda, Raimundo De Andrés, José L. Díaz, Marta Diéguez, María Riestra, José López-Miranda, Jesús Galiana, Jesús García-Cruces, Juan Antonio Garrido, Luis Irigoyen, Pedro L. Martínez, Lorena Suárez, Rosa M. Borrallo, Juan Diego Mediavilla, Fernando Jaén, Pablo González, Patricia Rubio, Pablo Miramontes, Juan L. Morera, Ovidio Muñiz, Aurora González, Francisca Pereyra, José Pastor, José Miguel Pinilla, Manuel J. Romero, Enrique Ruiz, M. Pilar Álvarez, Pedro Sáenz, Juan F. Sánchez, Consuelo Sanz, Jose I. Vidal

Publikováno v: Revista Española de Cardiología. 73:828-834

Resumen Introduccion y objetivos El estudio SAFEHEART se diseno para analizar la situacion y mejorar el conocimiento de la hipercolesterolemia familiar heterocigota (HFH) en Espana. Nuestro objetivo es determinar la tasa de incidencia de eventos card

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee0f309cc4b8725268b13317ddfbc214
https://doi.org/10.1016/j.recesp.2019.10.013